FiftyFifty.eu, social magazine
FiftyFifty.eu


Milk: hope for patients with HIV and chronic hepatitis

Milk: hope for patients with HIV and chronic hepatitis Chronic hepatitis C has been recently still incurable disease. Advances in modern medicine, but they started to win and infectious disease of the liver tissue. The most common reason for treatment failure is present dreaded infection with HIV. Swiss scientists but they come with a new triumph, discreet plantlet milk thistle Marian.


The dreaded complication of treatment

Coinfection or current infection with hepatitis C virus and HIV causes many doctors wrinkles in the compilation of successful treatment. According to statistics suffers double infection in the Czech Republic about 10% infected. The situation is even more desperate in the United States, where the share of co-infection is around 25-30%. Both viruses are transmitted mainly infected blood or body fluids. Not surprisingly, a large proportion of patients consists of injecting drug users. Generally, coinfection worsens the course of both diseases but also increases the probability of failure of therapy.

Miraculous thistle

Milk thistle is relatively inconspicuous plant. In medical circles, however, is invaluable in the treatment of liver diseases. Milk contains, silibinin active substance, which has beneficial effects on liver health. What is its strength?

Silibinin is a powerful antioxidant that protects liver cells from damage.
Its effect is to amplify the cell membranes, allowing better withstand the adverse effects, including viral infection.
Another essential component of the treatment effect of silibinin on regeneration of liver tissue. The extract of milk thistle supports the growth of liver cells and liver helps restore their function.

Swiss research

Switzerland demonstrates its quality not only in the manufacture of precision watches. The local scientists probably found a way to improve the prospects of patients coinfected with hepatitis C and HIV. Do the research were included patients with coinfection and current advanced liver disease. These individuals have only a 30% chance of successful treatment. Before they themselves antiviral therapy physicians They prescribed intravenous administration of high doses of silibinin for two weeks. After undergoing treatment with interferon, ribavirin and telaprevir. The results were truly astounding. Success in treating reached a full 80% of patients!

Scientists believe they have discovered a promising way in the modern treatment of patients with co-infection. Currently, it is necessary to wait for further results that confirm or disprove the beneficial effects of silibinin before starting antiviral treatment.


Source: Viral hepatitida.cz



Like FiftyFifty article:

All articles 2018, 2017, 2016, 2015, 2014, 2013 on FiftyFifty.eu